Remove 2012 Remove Cell Biology Remove Drug Development Remove Regulations
article thumbnail

TACACICLIB, AUR-102, AURIGENE

New Drug Approvals

As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,

article thumbnail

Precision Medicine in the Genomic Era

DrugBank

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care. & Barbadilla, A.

Disease 87